United States - English - NLM (National Library of Medicine)

king bio inc. - aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bellis perennis (unii: 2hu33i03uy) (bellis perennis - unii:2hu33i03uy), causticum (unii: dd5fo1wkfu) (causticum - unii:dd5fo1wkfu), collinsonia canadensis root (unii: o2630f3xdr) (collinsonia canadensis root - unii:o2630f3xdr), goldenseal (unii: zw3z11d0jv) (goldenseal - unii:zw3z11d0jv), skim milk (unii: 6a001y4m5a) (skim milk - unii:6a001y4m5a), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), strychnos nux-vo - aluminum oxide 10 [hp_x] in 59 ml - uses for temporary relief of symptoms of constipation: irregularity, hard, dry stools, great straining, rumbling and bloated bowels, mucus in stools, associated headache. uses for temporary relief of symptoms of constipation: - irregularity - hard, dry stools - great straining - rumbling and bloated bowels - mucus in stools - associated headache.

United States - English - NLM (National Library of Medicine)

king bio inc. - hpus active ingredients, equal volumes of each ingredient in 10x, 30x and lm1 potencies., alumina, bellis perennis, causticum, collinsonia canadensis, hydrastis canadensis, lac defloratum, natrum muriaticum, nux vomica, plumbum metallicum, sepia - ​ hpus active ingredients purpose† ​equal volumes of each ingredient in 10x, 30x, and lm1 potencies. alumina...........................................................................hard, dry stools bellis perennis................................................................rumbling in bowels, bloatedness causticum......................................................................mucous-covered stools collinsonia canadensis..................................................obstinate constipation, flatulence hydrastis canadensis.....................................................smarting pain in rectum, headache lac defloratum...............................................................hard stools with great straining natrum muriaticum........................................................pinching pain in abdomen nux vomica....................................................................ineffectual urging, constant uneasiness plumbum metallicum......................................................

United States - English - NLM (National Library of Medicine)

natural creations, inc. - aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), matricaria recutita (unii: g0r4ubi2zz) (matricaria recutita - unii:g0r4ubi2zz), graphite (unii: 4qqn74lh4o) (graphite - unii:4qqn74lh4o), lycopodium clavatum spore (unii: c88x29y479) (lycopodium clavatum spore - unii:c88x29y479), strychnos nux-vomica seed (unii: 269xh13919) (strychnos nux-vomica seed - unii:269xh13919), silicon dioxide (unii: etj7z6xbu4) (s - aluminum oxide 30 [hp_c] in 1 ml - uses: temporarily relieves infrequent bowel movements, difficult passage of stool &/or other symptoms of constipation.** uses: temporarily relieves infrequent bowel movements, difficult passage of stool &/or other symptoms of constipation.**

United States - English - NLM (National Library of Medicine)

natural creations, inc. - magnesium carbonate (unii: 0e53j927na) (carbonate ion - unii:7ujq5ope7d), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), aesculus hippocastanum flower (unii: kk0z92ii8m) (aesculus hippocastanum flower - unii:kk0z92ii8m), potassium alum (unii: 1l24v9r23s) (aluminum hydroxide - unii:5qb0t2iun0), aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), strychnos nux-vomica seed (unii: 269 - magnesium carbonate 3 [hp_x] in 1 ml - uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation. uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation.

United States - English - NLM (National Library of Medicine)

natural health supply - magnesium cation (unii: t6v3lhy838) (magnesium cation - unii:t6v3lhy838) - magnesium cation 30 [hp_c] in 1 ml - indications: to be used for acute self-limiting conditions according to standard homeopathic indications purpose: constipation billousness

United States - English - NLM (National Library of Medicine)

natural health supply - arsenic (unii: n712m78a8g) (arsenic - unii:n712m78a8g) - arsenic 30 [hp_c] - indications: to be used for acute self-limiting conditions according to standard homeopathic indications purpose: constipation

Malta - English - Medicines Authority

mylan products limited - lipase; amylase; protease - capsule - lipase 10000 u; amylase 8000 u; protease 600 u - digestives, incl. enzymes

Malta - English - Medicines Authority

mylan products limited - lipase; amylase; protease - capsule - lipase 25000 u; amylase 18000 u; protease 1000 u - digestives, incl. enzymes

United States - English - NLM (National Library of Medicine)

vivus llc - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancreaze is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects on the breastfed infant or the effects on milk production. pancrelipase is minimally absorbed systemically following oral administration, therefore maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for pancreaze and any potential adverse effects on the breastfed infant from pancreaze or from the underlying maternal condition. the safety and effectiveness of pancreaze for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients. use of pancreaze for this indication is supported by an adequate and well-controlled trial in adult and pediatric patients 8 to 17 years of age (study 1) along with supportive data from a randomized, investigator-blinded, dose-ranging study in 17 pediatric patients aged 6 to 30 months (study 2). both study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. the safety in pediatric patients in these studies was similar to that observed in adult patients [see adverse reactions (6.1) and clinical studies (14)] . dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. if there is a history of fibrosing colonopathy, monitor patients during treatment with pancreaze because some patients may be at risk of progressing to stricture formation. do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation . [see dosage and administration (2.2)and warnings and precautions (5.1)] . crushing or chewing pancreaze capsules or mixing the capsule contents in foods having a ph greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see dosage and administration (2.3)and warnings and precautions (5.2)]. clinical studies of pancreaze did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between patients aged 65 years and over and younger adult patients.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - capsium     6c, hydrastis can     6c, leptandra     6c, nux vom     6c, podophyllinum     6c - to relieve the symptoms of constipation that has lasted several days.  not a laxative. indications: capsium    fever hydrastis can    sinuses leptandra       constipation nux vom   vomiting podophyllinum   diarrhea if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.